Alverine citrate with simeticone oral
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Oral formulations containing alverine citrate with simeticone.
Drugs List
Therapeutic Indications
Uses
Irritable bowel syndrome
Dosage
Adults
One capsule 2 or 3 times a day at the beginning of meals.
Contraindications
Children under 18 years
Breastfeeding
Gastrointestinal obstruction
Paralytic ileus
Pregnancy
Precautions and Warnings
Contains soya or soya derivative
Discontinue if jaundice or other evidence of hepatic impairment occurs
Refer to doctor if symptoms persist after 2 weeks treatment
Pregnancy and Lactation
Pregnancy
Alverine citrate with simeticone is contraindicated during pregnancy.
The manufacturer recommends that as a precautionary measure, it is advisable to avoid the use of alverine citrate with simeticone capsules during pregnancy. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. No malformative or feto/neonatal toxicity has been observed with alverine citrate. There are no data from the use of simeticone or the combination in pregnant women.
Lactation
Alverine citrate with simeticone is contraindicated during breastfeeding.
The manufacturer recommends that as a precautionary measure, it is advisable to avoid the use of alverine citrate with simeticone capsules during breastfeeding. It is unknown whether alverine citrate or simeticone are excreted in human milk.
Side Effects
Anaphylactic reaction
Anaphylactic shock
Angioedema
Cytolytic hepatitis
Headache
Increase in alkaline phosphatase
Increase of liver transaminases
Nausea
Pruritus
Rash
Serum bilirubin increased
Urticaria
Vertigo
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: October 2020
Reference Sources
Summary of Product Characteristics: SimAlvia 60 mg/300 mg, soft capsules. Laboratories Galeniques Vernin. Revised March 2020.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.